Deletion of Chromosome 20q: Friend or foe?

Leukemia Research

Volumn 35, Issue 7, 2011, Pages 844-845

  Hasserjian, Robert P ^a   Dal Cin, Paola ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Cytogenetics; Del(20q); Myelodysplastic syndrome

Indexed keywords

L3MBTL1 PROTEIN; POLYCOMB GROUP PROTEIN; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; BLAST CELL; CANCER CLASSIFICATION; CANCER SURVIVAL; CARCINOGENESIS; CELL COUNT; CHROMOSOME DELETION; CHROMOSOME DELETION 20Q; DISEASE COURSE; EDITORIAL; FLUORESCENCE IN SITU HYBRIDIZATION; GENE LOSS; GENOMIC INSTABILITY; HUMAN; KARYOTYPE; KARYOTYPING; MALIGNANT TRANSFORMATION; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; RETICULOCYTE COUNT; THROMBOCYTOPENIA; TUMOR SUPPRESSOR GENE;

CHROMOSOME ABERRATIONS; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 20; HUMANS; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; SURVIVAL RATE;

EID: 79958709459     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2011.03.031     Document Type: Editorial

References (18)

1. Braun T., de Botton S., Taksin A.L., et al. Characteristics and outcome of myelodysplastic syndromes (MDS) with isolated 20q deletion: a report on 62 cases. Leuk Res 2011, 35:863-867.
2. Crescenzi B., La Starza R., Sambani C., et al. Totipotent stem cells bearing del(20q) maintain multipotential differentiation in Shwachman Diamond syndrome. Br J Haematol 2009, 144:116-119.
3. Nilsson T., Nilsson L., Lenhoff S., et al. MDS/AML-associated cytogenetic abnormalities in multiple myeloma and monoclonal gammopathy of undetermined significance: evidence for frequent de novo occurrence and multipotent stem cell involvement of del(20q). Genes Chromosomes Cancer 2004, 41:223-231.
4. Gurvich N., Perna F., Farina A., et al. L3MBTL1 polycomb protein, a candidate tumor suppressor in del(20q12) myeloid disorders, is essential for genome stability. Proc Natl Acad Sci USA 2010, 107:22552-22557.
5. Alanio-Brechot C., Schischmanoff P.O., Feneant-Thibault M., et al. Association between myeloid malignancies and acquired deficit in protein 4. 1R: a retrospective analysis of six patients. Am J Hematol 2008, 83:275-278.
6. Douet-Guilbert N., Basinko A., Morel F., et al. Chromosome 20 deletions in myelodysplastic syndromes and Philadelphia-chromosome-negative myeloproliferative disorders: characterization by molecular cytogenetics of commonly deleted and retained regions. Ann Hematol 2008, 87:537-544.
7. Douet-Guilbert N., Lai J.L., Basinko A., et al. Fluorescence in situ hybridization characterization of ider(20q) in myelodysplastic syndrome. Br J Haematol 2008, 143:716-720.
8. Li T., Xue Y., Zhang J., et al. Isodicentric 20q-in two cases of B-cell acute lymphocytic leukemia with the respective t(9;20)(p11;q11. 2) and t(9;22)(q34;q11. 2). Cancer Genet Cytogenet 2008, 181:55-59.
9. Ligon A.H., DeAngelo D.J., Atkins L., et al. Isochromosome of a deleted 20q may be a relatively common abnormality in myeloid malignancies. Cancer Genet Cytogenet 2005, 162:89-91.
10. Liu Y.C., Ito Y., Hsiao H.H., et al. Risk factor analysis in myelodysplastic syndrome patients with del(20q): prognosis revisited. Cancer Genet Cytogenet 2006, 171:9-16.
11. Kurtin P.J., Dewald G.W., Shields D.J., et al. Hematologic disorders associated with deletions of chromosome 20q: a clinicopathologic study of 107 patients. Am J Clin Pathol 1996, 106:680-688.
12. Qian Z., Joslin J.M., Tennant T.R., et al. Cytogenetic and genetic pathways in therapy-related acute myeloid leukemia. Chem Biol Interact 2010, 184:50-57.
13. Bacher U., Schnittger S., Kern W., et al. Distribution of cytogenetic abnormalities in myelodysplastic syndromes. Philadelphia negative myeloproliferative neoplasms, and the overlap MDS/MPN category. Ann Hematol 2009, 88:1207-1213.
14. Barlogie B., Tricot G., Haessler J., et al. Cytogenetically defined myelodysplasia after melphalan-based autotransplantation for multiple myeloma linked to poor hematopoietic stem-cell mobilization: the Arkansas experience in more than 3,000 patients treated since 1989. Blood 2008, 111:94-100.
15. Liu Y.C., Miyazawa K., Sashida G., et al. Deletion (20q) as the sole abnormality in Waldenstrom macroglobulinemia suggests distinct pathogenesis of 20q11 anomaly. Cancer Genet Cytogenet 2006, 169:69-72.
16. Sun J., Yin C.C., Cui W., et al. Chromosome 20q deletion: a recurrent cytogenetic abnormality in patients with chronic myelogenous leukemia in remission. Am J Clin Pathol 2011, 135:391-397.
17. Soupir C.P., Vergilio J.A., Kelly E., et al. Identification of del(20q) in a subset of patients diagnosed with idiopathic thrombocytopenic purpura. Br J Haematol 2009, 144:800-802.
18. Steensma D.P., Dewald G.W., Hodnefield J.M., et al. Clonal cytogenetic abnormalities in bone marrow specimens without clear morphologic evidence of dysplasia: a form fruste of myelodysplasia?. Leuk Res 2003, 27:235-242.